Trevena (NASDAQ: TRVN) and Auris Medical (NASDAQ:EARS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Risk and Volatility

Trevena has a beta of -0.58, meaning that its share price is 158% less volatile than the S&P 500. Comparatively, Auris Medical has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Trevena and Auris Medical, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trevena 0 1 9 0 2.90
Auris Medical 0 0 2 0 3.00

Trevena presently has a consensus price target of $8.65, indicating a potential upside of 402.91%. Auris Medical has a consensus price target of $4.50, indicating a potential upside of 818.37%. Given Auris Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Auris Medical is more favorable than Trevena.

Institutional & Insider Ownership

56.1% of Trevena shares are owned by institutional investors. Comparatively, 25.2% of Auris Medical shares are owned by institutional investors. 4.6% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Trevena and Auris Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trevena N/A -150.22% -94.66%
Auris Medical N/A -343.01% -80.81%

Earnings and Valuation

This table compares Trevena and Auris Medical’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Trevena $3.75 million 28.57 -$102.99 million ($1.65) -1.04
Auris Medical N/A N/A -$31.13 million ($0.65) -0.75

Auris Medical has lower revenue, but higher earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Auris Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Auris Medical beats Trevena on 7 of the 12 factors compared between the two stocks.

About Trevena

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

About Auris Medical

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.